Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer
Ahmed, A.; Charoentong, P.; Klotz, R.; Koehler, S.; Suarez-Carmona, M.; Valous, N. A.; Ferber, D.; Heikenwaelder, M.; Giese, N.; Hackert, T.; Klupp, F.; Schneider, M.; Schmidt, T.; Springfeld, C.; Tanriver, Y.; Falk, C. S.; Zitvogel, L.; Zoernig, I.; Jaeger, D.; Halama, N.
Show abstract
Induction of anti-tumor immunity in pancreatic ductal adenocarcinoma (PDA) is an unresolved challenge. Systematic investigation of the microenvironment of primary pancreatic tumors revealed a role of endocrine Langerhans islets in the coordination of immune activation. We found that intratumoral {beta}-cells, regulated via STAT3, secrete C-C motif chemokine ligand 27 (CCL27) and thereby promote a TH1 phenotype in the microenvironment resulting in an enhanced T cell infiltration and prolonged patient survival. The local effect can be abrogated in a patient-based human explant model by inhibition of the CCL27 receptor CCR10. This defense mechanism is paralleled by an impaired metabolic function of Langerhans islets with reduced insulin levels resulting in a dysregulation of glycemic control in patients. Based on these findings, screening of PDA cases (n= 2264) led to the identification of type 2 diabetes mellitus (T2DM) and extractable glycated haemoglobin (HbA1c) levels as response markers for neoadjuvant chemotherapy with fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX). Collectively these data provide insights into the interconnection of T2DM and PDA, and link declining glycemic control to therapeutic efficacy, which can be utilized as a tool for clinical decision-making and improve patient management.
Matching journals
The top 15 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Identification and implication of tissue-enriched ligands in epithelial-endothelial crosstalk during pancreas development 94%
- Bringing the pancreas patient back to the bench: Ex vivo culture of intact human patient derived pancreatic tumour tissue 94%
- Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses 94%
Similar papers in this journal
- Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia 94%
- Inhibition of mitochondrial dynamics preferentially targets pancreatic cancer cells with enhanced tumorigenic and invasive potential 94%
- Colorectal cancer progression is potently reduced by a glucose-free, high-protein diet: comparison to anti-EGFR therapy 93%
Similar papers in this journal
- Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice 96%
- CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming 95%
- Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model. 94%
Similar papers in this journal
- Immunomodulatory effects of tumor Lactate Dehydrogenase C (LDHC) in breast cancer 94%
- Immunosuppressants Rewire the Gut Microbiome-Alloimmune Axis Through Time-Dependent and Tissue-Specific Mechanisms 93%
- MiRNA-10b marks aggressive squamous cell carcinomas, and confers a cancer stem cell-like phenotype 92%